Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1

Pramod K. Mistry, Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T. Andrew Burrow, Joel Charrow, Gerald F. Cox, Sumita Danda, Marta Dragosky, Guillermo Drelichman, Amal El-Beshlawy, Cristina Fraga, Selena Freisens, Sebastiaan Gaemers, Evgueniy Hadjiev, Priya S. Kishnani, Elena Lukina, Pierre Maison-Blanche, Ana Maria Martins, Gregory PastoresMilan Petakov, M. Judith Peterschmitt, Hanna Rosenbaum, Barry Rosenbloom, Lisa H. Underhill, Timothy M. Cox*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)71-74
Number of pages4
JournalBlood Cells, Molecules, and Diseases
Volume71
DOIs
StatePublished - Jul 2018

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this